Phase II study of capecitabine and irinotecan as first-line treatment in metastatic colorectal cancer: First trial of the Brazilian Oncology Consortium (BOC-CRC 001)
| Autor: | A. Del Giglio, F. Viola, L. Camillo-Coura, Carlos H. Barrios, R. F. Silva, C. Mathias |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Tumor differentiation Colorectal cancer business.industry medicine.medical_treatment Phases of clinical research medicine.disease Capecitabine Irinotecan First line treatment Internal medicine medicine Thymidine phosphorylase business Adjuvant medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 22:3725-3725 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2004.22.90140.3725 |
| Popis: | 3725 Background: Capecitabine and Irinotecan have different mechanisms of action and are both active in colorectal cancer (CRC). Capecitabine is activated by intratumoral thymidine phosphorylase and this enzyme may be up-regulated by irinotecan. The combination of these two drugs is tested in this multicenter phase II trial, the first of a new cooperative group: Brazilian Oncology Consortium (BOC CRC-001). Methods: A total of 37 pts with measurable metastatic CRC were included. 21men (57%) and 16 women (43%); median age 53.6 (23–74). Most pts were ECOG PS 0 29/35 (82%), 5% were PS 2. Tumor differentiation was GII in 75% and GIII/IV in 14% of the cases. Liver involvement was present in 65% of the pts. 13/37 (35%) of the pts had received previous adjuvant 5FU/LV. The treatment regimen included Capecitabine 1000mg/m2 PO twice daily for 14 days and Irinotecan 75mg/m2 IVover 90 min d1and 8. Cycles repeated every 3 weeks. Patients >65 years old received lower doses of both agents (750/60) and were required to h... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|